Morphic Therapeutic, Inc. clinical trials
Acquired by Eli Lilly and Company, Aug 16, 2024 · source ↗
The registry lists 5 studies whose lead sponsor is Morphic Therapeutic, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 4, 2026.
- 5studies on the registry
- 1open to participants now
Before and after it joined Eli Lilly and Company
- First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company
- 4
- First submitted after Morphic Therapeutic, Inc. became part of Eli Lilly and Company
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Morphic Therapeutic, Inc.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 20
- 21
- 222
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)5 studies
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Eli Lilly and Company studies →
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06226883Phase 2
Sponsor listed in the registry: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company
- A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCCompletedNCT05611671Phase 2
Sponsor listed in the registry: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company
- A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy ParticipantsCompletedNCT06977880Phase 1
Sponsor listed in the registry: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · First submitted after Morphic Therapeutic, Inc. became part of Eli Lilly and Company
- A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UCCompletedNCT05291689Phase 2
Sponsor listed in the registry: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company
- Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy VolunteersCompletedNCT04580745Phase 1
Sponsor listed in the registry: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company